EC Clinical and Medical Case Reports

Sarcoidosis represents as a multi-system disorder associated with granulomatous inflammation. Cutaneous lesions are encountered in up to 35% instances.

 Of obscure aetiology, disease occurrence and progression may be concordant to deranged immune response towards extrinsic antigens, especially within genetically susceptible individuals. Clinically, the disorder appears heterogeneous and may simulate diverse dermatological conditions.

1. Bokhari SRA., et al. “Sarcoidosis”. Stat Pearls International. Treasure Island, Florida (2025).
2. Waly YM., et al. “A review of sarcoidosis etiology, diagnosis and treatment”. Frontiers in Medicine (Lausanne) 12 (2025): 1558049.
3. Coker RK and Cullen KM. “Sarcoidosis: Key disease aspects and update on management”. Clinical Medicine (London)3 (2025): 100326.
4. Xu D., et al. “Sarcoidosis: molecular mechanisms and therapeutic strategies”. Molecular Biomedicine 1 (2025): 6.
5. Rivera NV. “Big data in sarcoidosis”. Current Opinion in Pulmonary Medicine 5 (2024): 561-569.
6. Belfeki N., et al. “Current concepts on pathogenesis, diagnosis and management of hepatic sarcoidosis”. Rheumatology International 5 (2025): 130.
7. Belperio JA., et al. “Diagnosis and treatment of pulmonary sarcoidosis: a review”. Journal of the American Medical Association 9 (2022): 856-867.
8. Obi ON., et al. “Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches”. Frontiers in Medicine (Lausanne) 9 (2022): 991783.
9. Image 1 Courtesy: Pathology outlines.
10. Image 2 Courtesy: Springer link.